An observational study in Pediatric ALL and Stone, Urinary, sponsored by Azienda Ospedaliero-Universitaria di Parma. Completed at 1 site in Italy. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-10-30.
Sponsored by Azienda Ospedaliero-Universitaria di Parma · Observational
Among 148 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy — 29 open to participants now, 43 under way, 10 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Italy.
Among the 148 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy, this one is the 19th largest by enrollment of the 28 observational ones that give a count, is one of 11 that started in 2019, is one of 28 observational ones, and was the 109th registered.
2,584 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
This study's enrollment of 70 is below the median of 108 across 400 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →29 of the 148 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy are open now, in 12 countries. Each count lists the studies.
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 0 Years to 17 Years · all sexes.
The full table on the hub →148 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 11 started in 2019.
Median enrollment 98 across the 118 interventional studies, 100 across the 28 observational. Of the 86 that completed or were terminated, 40 (47%) have results posted.
57 of 148 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria di Parma is the lead sponsor of 44 studies on the registry; 13 are open to participants now.
Azienda Ospedaliero-Universitaria di Parma has 3 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
10 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04722848Phase 3Gruppo Italiano Malattie EMatologiche dell'AdultoSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | 2027-09 |
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT04232241Universitätsklinikum Hamburg-EppendorfMatched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | 2026-11-22 |
| NCT05366569Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBio-CAR-T BS Study | 2026-12-31 |
| NCT05397496Novartis PharmaceuticalsStudy of PIT565 in Relapsed and/or Refractory B-cell Malignancies | 2027-01-04 |
Among the 148 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy, from their registry updates:
Incidence of paediatric urolithiasis is increasing in Europe and North America. Nowadays the management of stone disease is a common practice in not endemic country. The surgical's treatment is based on similar techniques as for adults. In the last years due to miniaturization of endoscopic instruments endourology has become the best approach to treat urinary stones in children. The investigators have retrospectively reviewed experience from 01/01/2000 to 28/02/2019 in children ≤ 16 years old affected by urinary stones who underwent rigid and flexible ureterorenoscopy and pecutaneous nephrolitotripsy procedures and recorded clinical data, overall success rate and complication.
0-17 yrs old, urinary stones (kidney, ureteral, not bladder), with or without malformations or metabolic diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
stone free rate
no stones or residual fragment \< 4 mm
Time frame: immediately
stone free rate
no stones or residual fragment \< 4 mm
Time frame: 3 months follow up
complication rate
clavien-dindo classification
Time frame: immediately
complication rate
clavien-dindo classification
Time frame: 3 months follow up
Ran from Jul 2019 to primary completion in Aug 2019, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Azienda Ospedaliero-Universitaria di Parma